Trial intelligence / Profile preview

Thermotherapy and Short Course Miltefosine for Uncomplicated Cutaneous Leishmaniasis

NCT02687971Phase 2Completed

Sponsor
Drugs for Neglected Diseases initiative
Start
Dec 2016
Primary completion
Aug 2019
Modality
Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
Countries
2
01

Overview

A Phase 2 trial of miltefosine in cutaneous leishmaniasis (CL), sponsored by Drugs for Neglected Diseases initiative. Started Dec 2016; status: completed.

02

Drugs

miltefosine
03

Conditions

cutaneous leishmaniasis (CL)

Beyond the preview

Go deeper on NCT02687971.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02687971.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call